Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Shares Outstanding (Diluted Average) (2021 - 2025)

Heron Therapeutics' Shares Outstanding (Diluted Average) history spans 5 years, with the latest figure at $166.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 9.35% year-over-year to $166.7 million; the TTM value through Dec 2025 reached $166.7 million, up 9.35%, while the annual FY2025 figure was $166.7 million, 9.35% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $166.7 million in Q4 2025 per HRTX's latest filing, down from $170.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $170.3 million in Q3 2025 to a low of $98471.0 in Q4 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $121.8 million, with a median of $119.7 million recorded in 2023.
  • The largest YoY upside for Shares Outstanding (Diluted Average) was 110466.56% in 2022 against a maximum downside of 3.87% in 2022.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $98471.0 in 2021, then surged by 110466.56% to $108.9 million in 2022, then rose by 26.87% to $138.1 million in 2023, then rose by 10.36% to $152.4 million in 2024, then rose by 9.35% to $166.7 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Shares Outstanding (Diluted Average) are $166.7 million (Q4 2025), $170.3 million (Q3 2025), and $152.4 million (Q4 2024).